文献速递复苏、休克与脓毒症心脑血管急症重症综合管理与镇静镇痛

高危急性肺栓塞的管理:一项模拟目标试验分析

Management of high-risk acute pulmonary embolism: an emulated target trial analysis.
PubMed 文献 · Intensive Care Med · 2025-02-25
一句话结论在模拟目标试验中,高危急性肺栓塞患者接受全身溶栓、外科血栓切除或经皮导管治疗,院内死亡概率均低于单纯VA-ECMO。

该观察性研究纳入1060例高危急性肺栓塞患者,其中991例进入模拟目标试验,比较单纯VA-ECMO(n=126)、院内全身溶栓(n=643)、外科血栓切除(n=49)和经皮导管治疗(n=173)四种策略的院内全因死亡。主要分析显示,单纯VA-ECMO估计院内死亡概率为57%(95%CI 47%;67%),全身溶栓为48%(95%CI 44%;53%),外科血栓切除为34%(95%CI 18%;50%),经皮导管治疗为43%(95%CI 35%;51%);死亡风险比总体支持任一种再通策略优于单纯VA-ECMO,且所有敏感性分析支持该结果。作者认为,与单纯VA-ECMO作为桥接恢复相比,全身溶栓、外科血栓切除及若干有前景的导管系统等再通策略可能对高危肺栓塞患者的短期生存产生积极影响。

要点

  • 在模拟目标试验中,单纯VA-ECMO组估计院内死亡概率为57%(95%CI 47%;67%),高于全身溶栓的48%(95%CI 44%;53%)、外科血栓切除的34%(95%CI 18%;50%)和经皮导管治疗的43%(95%CI 35%;51%)。
  • 死亡风险比总体支持任一种再通策略优于单纯VA-ECMO,且所有敏感性分析支持该结果。
  • 全身溶栓组(n=643)占目标试验人群的大多数,外科血栓切除组(n=49)样本量小。
  • 在粗结局分析中,各治疗组存活出院患者获得良好神经功能结局的概率均较高。
  • VA-ECMO在全身溶栓、外科血栓切除和经皮导管治疗组中允许作为桥接再通治疗。

适用人群与场景

  • 接受高危急性肺栓塞治疗的患者,共1060例,其中991例纳入模拟目标试验。
  • 目标试验人群的中位年龄为62.0岁,53.3%为男性。

处置流程与药物剂量

  • 四种治疗策略:单纯VA-ECMO(n=126)、院内全身溶栓(n=643)、外科血栓切除(n=49)、经皮导管治疗(n=173)。
  • VA-ECMO在全身溶栓、外科血栓切除和经皮导管治疗组中允许作为桥接再通治疗。

研究设计与关键结果

  • 研究类型:观察性研究,采用模拟目标试验分析;总人群1060例,991例纳入目标试验。
  • 主要终点为院内全因死亡;采用g-formula结合逻辑回归模型估计边际因果对比,敏感性分析包括TMLE结合机器学习、IPTW、不同估计目标、缺失值处理及排除单纯VA-ECMO组的完整目标试验模拟。
  • 估计院内死亡概率:单纯VA-ECMO 57%(95%CI 47%;67%),院内全身溶栓48%(95%CI 44%;53%),外科血栓切除34%(95%CI 18%;50%),经皮导管治疗43%(95%CI 35%;51%)。
  • 死亡风险比总体支持任一种再通策略优于单纯VA-ECMO,所有敏感性分析支持该结果的稳健性。
  • 粗结局分析中,各治疗组存活出院患者获得良好神经功能结局的概率均较高。

证据类型、等级与局限

  • 证据类型:观察性研究(模拟目标试验分析)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,与单纯VA-ECMO作为桥接恢复相比,全身溶栓、外科血栓切除及若干有前景的导管系统等再通策略可能对高危肺栓塞患者的短期生存产生积极影响。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: High-risk acute pulmonary embolism (PE) is a life-threatening condition necessitating hemodynamic stabilization and rapid restoration of pulmonary perfusion. In this context, evidence regarding the benefit of advanced circulatory support and pulmonary recanalization strategies is still limited.

METHODS: In this observational study, we assessed data of 1060 patients treated for high-risk acute PE with 991 being included in a target trial emulation to investigate all-cause in-hospital mortality estimates with different advanced treatment strategies. The four treatment groups consisted of patients undergoing (I) veno-arterial extracorporeal membrane oxygenation (VA-ECMO) alone (n = 126), (II) intrahospital systemic thrombolysis (SYS) (n = 643), (III) surgical thrombectomy (ST) (n = 49), and (IV) percutaneous catheter-directed treatment (PCDT) (n = 173). VA-ECMO was allowed as bridging to pulmonary recanalization in groups II, III, and IV. Marginal causal contrasts were estimated using the g-formula with logistic regression models as the primary approach. Sensitivity analyses included targeted maximum likelihood estimation (TMLE) with machine learning, inverse probability of treatment weighting (IPTW), as well as variations of estimands, handling of missing values, and a complete target trial emulation excluding the VA-ECMO alone group.

RESULTS: In the overall target trial population, the median age was 62.0 years, and 53.3% of patients were male. The estimated probability of in-hospital mortality from the primary target trial intention-to-treat analysis for VA-ECMO alone was 57% (95% confidence interval [CI] 47%; 67%), compared to 48% (95% CI 44%; 53%) for intrahospital SYS, 34% (95%CI 18%; 50%) for ST, and 43% (95% CI 35%; 51%) for PCDT. The mortality risk ratios were largely in favor of any advanced recanalization strategy over VA-ECMO alone. The robustness of these findings was supported by all sensitivity analyses. In the crude outcome analysis, patients surviving to discharge had a high probability of favorable neurologic outcome in all treatment groups.

CONCLUSION: Advanced recanalization by means of SYS, ST, and several promising catheter-directed systems may have a positive impact on short-term survival of patients presenting with high-risk PE compared to the use of VA-ECMO alone as a bridge to recovery.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Stadlbauer A, Verbelen T, Binzenhöfer L, et al. Management of high-risk acute pulmonary embolism: an emulated target trial analysis. Intensive Care Med. 2025. PMID: 39998658. doi:10.1007/s00134-025-07805-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。